BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion

Inclusion Criteria: * COHORT A (INCLUDING SAFETY RUN IN, STAGE I AND STAGE II) AND COHORT B: * Patients must have pathologically or cytologically confirmed metastatic solid tumor of gastrointestinal origin with MTAP deletion including pancreatic cancer, biliary cancer, esophageal cancer and colon cancer (Cohort A) or other metastatic solid malignancy with MTAP deletion (Cohort B) confirmed by validated next generation sequencing tissue techniques only * NOTE: Both internal and external validated next generation sequencing (NGS) panels are acceptable * Progressive disease (PD) after one previous standard of care line of treatment * NOTE: symptoms from clinical evaluation for PD will be sufficient * Patients must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1, measured preferably by computed tomography (CT) scan * Note: Tumor lesions in a previously irradiated area are not considered measurable unless they show unequivocal progression * NOTE: There is no limit on previous treatment lines * Patients who have received any neoadjuvant or systemic chemotherapy are eligible * Note: treatment cannot have included prior pemetrexed unless in the case of non-small cell lung cancer (NSCLC) cancer type. Any prior intravesical therapy, or immunotherapy is allowed. At least 3 weeks (21 days) wash-out period from treatment since prior chemotherapy or radiation therapy or targeted agent is required * Patients must be …